FDA budget cuts proposed for fiscal 1998 are "troubling," patient groups tell HHS.
Executive Summary
FDA FY 1998 BUDGET PROPOSAL RISKS "WEAKENING" AGENCY, PATIENT GROUPS assert in a Feb. 12 letter to HHS Secretary Shalala. Members of the Patients' Coalition write that "the medical device and import user fees in the FY 1998 budget appear to be a deficit-reduction mechanism with the serious consequence of weakening FDA." The Clinton Administration budget proposal would cut federal appropriations to FDA by 8%, but would use new fees collected across the agency to produce a net 6% increase in funding, to $1.06 bil. ("The Pink Sheet" Feb. 10, p. 9).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth